Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 17, 2015

RAS Mutations and Panitumumab With FOLFIRI vs FOLFIRI Alone for Metastatic Colorectal Cancer

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab With FOLFIRI ComparedWith FOLFIRI Alone as Second-Line Treatment for Metastatic Colorectal Cancer
Clin. Cancer Res 2015 Sep 04;[EPub Ahead of Print], M Peeters, KS Oliner, TJ Price, et al

Further Reading